Inactivated SARS-Cov-2 Vaccine

Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone. Double-blind, randomized, placebo-controlled phase 1 (96 participants) and phase 2 (224 participants) were carried out in healthy adults between 18-59 years. Results from these trials showed low rates of adverse reactions and demonstrated immunogenicity. Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780).

Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone. Double-blind, randomized, placebo-controlled phase 1 (96 participants) and phase 2 (224 participants) were carried out in healthy adults between 18-59 years. Results from these trials showed low rates of adverse reactions and demonstrated immunogenicity. Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780).

No indication information available.

No associated conditions information available.